ClinicalTrials.gg
RecruitingNCT05800054Updated Apr 5, 2023

Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer

An interventional study of Nutritional Support Team and Docetaxel in Esophageal Neoplasms and Adverse Drug Event, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-05.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 7 months after the study started (first participant enrolled Jan 2021, registered Aug 2022).
  • Started Jan 2021; still recruiting 5 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a randomized, open, parallel controlled clinical trial. The main purpose of this study was to compare the changes in body weight/body mass index (BMI) before and after treatment between the two groups of patients with NST full-course nutritional management and without NST full-course nutritional management.

The secondary objective was to compare the quality of life, nutritional status, immune function and inflammatory response, adverse reactions of radiotherapy and chemotherapy, and short-term/long-term efficacy between the two groups.

The treatment plan was: esophageal cancer with routine nutrition guidance as the control group, and the NST whole-process intervention guidance as the experimental group.

1. Experimental group: NST whole-course intervention

  1. Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d, protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral can not meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation Ruineng, and/or whey protein powder.
  2. Radiotherapy
  3. Chemotherapy 2. Control group: routine nutrition guidance for esophageal cancer

(1) Nutritional therapy: The nutritional program was the same as that of the experimental group, and the patients performed it themselves.

(2) Concurrent chemoradiotherapy: the same as the experimental group.

Efficacy evaluation:

  1. Body weight and body mass index (BMI)
  2. Quality of life score (EORTCQLQ-C30)
  3. Nutritional status
  4. Immune function and inflammatory response (total lymphocytes, CRP, IL-6)

(4) Intestinal mucosal barrier and intestinal flora (5) Adverse reactions of radiotherapy and chemotherapy (6) Short-term/long-term efficacy (5) Evaluation of treatment side effects (6) Short-term/long-term efficacy

Read the detailed description

This study is a randomized, open, parallel controlled clinical trial. The main purpose of this study was to compare the changes in body weight/body mass index (BMI) before and after treatment between the two groups of patients with NST full-course nutritional management and without NST full-course nutritional management.

The secondary objective was to compare the quality of life, nutritional status, immune function and inflammatory response, adverse reactions of radiotherapy and chemotherapy, and short-term/long-term efficacy between the two groups.

The treatment plan was: esophageal cancer with routine nutrition guidance as the control group, and the NST whole-process intervention guidance as the experimental group.

1. Experimental group: NST whole-course intervention

  1. Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d, protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral can not meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation Ruineng, and/or whey protein powder.

    Enteral nutrition preparations should choose Nengquan, and the dose of Nengjian: (a) No/mild obstruction, can eat ordinary diet, the food intake is not reduced or less than 1/3 before the disease, and 10-15kcal of Nengjian is given. /kg/d; (b) moderate obstruction, can eat soft food, the food intake is less than 1/3\~2/3 before the disease, and can give 15-20kcal/kg/d; (c) severe obstruction, can not Eating, the food intake is reduced by >= 2/3 compared with that before the disease, and can be given 20-25kcal/kg/d of all-vegetarian food; Dosage of whey protein powder: (a) albumin 35\~40g/L, supplemented with whey protein powder 10g; (b) albumin 30\~35g/L, supplemented with whey protein powder 20g; (c) albumin \<30g /L, supplement whey protein powder 30g.

    Nutritionists urge patients to report daily to ensure adequate energy and protein supplementation.

  2. Radiotherapy: image-guided intensity-modulated radiotherapy (IGRT) or intensity-modulated radiotherapy (IMRT); the irradiation target areas include primary lesions, clinical target areas, positive lymph nodes, and lymph node drainage areas. Dose split/prescribed dose, 95% volume PGTV-T60-66Gy/30-35 times, PGTV-N 60-66Gy/30-35 times, PCTV-T 46-50Gy/23-25 times, PCTV-N46-50Gy/ 23-25 times.
  3. Chemotherapy: Docetaxel 60-75mg/m2, d1, DDP 25mg/m2 d1-3, 21-28d/cycle. Simultaneous with radiotherapy for at least 2 cycles, after radiotherapy, the choice of whether to continue adjuvant chemotherapy is based on specific circumstances.

2. Control group: routine nutrition guidance for esophageal cancer

  1. Nutritional therapy: The nutritional program was the same as that of the experimental group, and the patients performed it themselves.
  2. Concurrent chemoradiotherapy: the same as the experimental group.

Efficacy evaluation:

  1. Body weight and body mass index (BMI)
  2. Quality of life score (EORTCQLQ-C30)
  3. Nutritional status
  4. Immune function and inflammatory response (total lymphocytes, CRP, IL-6)

(4) Intestinal mucosal barrier and intestinal flora (5) Adverse reactions of radiotherapy and chemotherapy (6) Short-term/long-term efficacy (5) Evaluation of treatment side effects (6) Short-term/long-term efficacy Statistical methods: All statistical tests were two-sided, and P values \< 0.05 were considered statistically significant. Data are presented as x ±s. Quantitative data were analyzed by t test and variance analysis, qualitative data were analyzed by X2 test, and survival data were analyzed by Kaplan Meire method, logrank test, and Cox regression.

02

Conditions studied

  • Esophageal Neoplasms
  • Adverse Drug Event
03

In context

Esophageal Neoplasms

1,631 studies on the registry are indexed under Esophageal Neoplasms; 469 are open to participants now.

This study's planned enrollment of 210 is above the median of 60 across 1,198 interventional studies indexed under Esophageal Neoplasms.

Browse Esophageal Neoplasms studies →

Lead sponsor

The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 563 studies on the registry; 311 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the informed consent; must have good compliance with the treatment plan and follow-up.
  • No gender restriction, but age between 18 and 75 years old;
  • Cytological or histological is confirmed esophageal squamous cell carcinoma;
  • Non-surgical treatment of stage II-III primary esophageal cancer (except biopsy);
  • The primary tumor can be evaluated;
  • No distant organ metastasis;
  • PG-SGA score B (2\~8) or C (≥9);
  • KPS score ≥ 70 points, ECOG physical condition score 0-1 points;
  • The function of major organs (bone marrow, liver, kidney function) 7 days before treatment, meet the following criteria: Blood routine examination standards (without blood transfusion within 14 days):

    • Hemoglobin (HB) ≥ 100g/L;

      • White blood cells (WBC) ≥ 4×109/L; Absolute neutrophil count (ANC) ≥1.5×109/L;

        • Platelet (PLT) ≥ 100×109/L.
  • The biochemical examination shall meet the following standards:

    • Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN);

      • Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 1.5 times ULN;

        • Serum creatinine (Cr) ≤ 1.5 times ULN or creatinine clearance rate (CCr) ≥ 60ml/min.
  • Expected survival ≥ 6 months.

Exclusion criteria

Exclusion Criteria:

  • No malnutrition or nutritional risk; PG-SGA score of A;
  • Severely impaired intestinal function, or intolerance of enteral nutrition;
  • Severe vomiting, gastrointestinal bleeding, intestinal obstruction;
  • Patients with very severe malnutrition cannot tolerate radiotherapy and chemotherapy;
  • The primary tumor or lymph node has received radiotherapy, chemotherapy or targeted therapy;
  • Suffering from other malignant tumors within 5 years (except for completely cured cervical carcinoma in situ or skin basal cell carcinoma);
  • Subjects who have received other drug trials within the past month;
  • Those with severe allergic history or idiosyncratic constitution;
  • Those with a history of severe lung or heart disease;
  • Serious comorbidities, such as uncontrolled hypertension, heart failure, etc.;
  • Pregnant or breastfeeding women;
  • Currently or planning to participate in other clinical trials;
  • Refusal or inability to sign the informed consent form to accept participation in the trial.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    NST intervenes throughout the process

    1. Nutritionists formulate nutritional programs and manage them in a refined manner. The nutritionist urges the patient to report daily to ensure that the patient's energy and protein are in place 2. Radiotherapy 3. chemotherapy

    Dietary Supplement: Nutritional Support Team · Drug: Docetaxel · Drug: cisplatin · Radiation: Radiotherapy

  • Experimental
    Routine nutrition guidance group for esophageal cancer

    1. Patients perform their own nutrition regimen, and the nutritionist is not involved in management 2. Radiotherapy 3. chemotherapy

    Drug: Docetaxel · Drug: cisplatin · Radiation: Radiotherapy

Interventions

  • Dietary supplementNutritional Support Team

    Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal/kg/d, protein 1.2-1.5g/kg/d. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral intake cannot meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and/or the tumor nutritional preparation Ruineng, and/or whey protein powder.

    Also known as: taixinsheng

  • 60-75 mg/m2, d1, at least 2 cycles in parallel with radiotherapy

    Also known as: chemotherapy

  • cisplatin 25mg/m2 d1-3, 21-28d/cycle. at least 2 cycles in parallel with radiotherapy

    Also known as: chemotherapy

  • RadiationRadiotherapy

    image-guided intensity-modulated radiotherapy (IGRT) or intensity-modulated radiotherapy (IMRT); Irradiation targets include primary lesions, clinical targets, positive lymph nodes, and lymph node drainage areas. Dose splitting/prescription dose, 95% volume PGTV-T60-66Gy/30-35 times, PGTV-N 60-66Gy/30-35 times, PCTV-T 46-50Gy/23-25 times, PCTV-N46-50Gy/23-25 times.

06

What researchers measure

Primary outcomes

  1. Body weight and body mass index (BMI)

    BMI = weight ÷ height2. (Unit of weight: kg; Height unit: meters),During treatment: Body weight was recorded daily and BMI was recorded weekly,BMI values are recorded every Friday

    Time frame: up to 3 years

Secondary outcomes

  1. Quality of life score

    EORTCQLQ-C30,EORTC:The European O-rganization for Reasearch and Treatment of Cancer),QOL-C30 (Quality of Life Questionnare-Core 30,Assessments are conducted every two weeks on Fridays of the second week

    Time frame: up to 3 years

  2. hemoglobin

    Compare the numerical changes of hemoglobin every two weeks

    Time frame: up to 3 years

  3. serum albumin

    Compare the numerical changes of serum albumin every two weeks

    Time frame: up to 3 years

  4. ORR

    Proportion of patients with reduction in tumor burden of a predefined amount, including complete remission and partial remission

    Time frame: through study completion, an average of 36 month

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210009, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2024, 47 months after the start.

Of 178 non-industry interventional studies with no phase under Esophageal Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 98. This study's planned 47 months is close to that.

Counting every sponsor, half of 183 studies reached it within 51 months; a quarter within 28 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2022
First posted
Apr 5, 2023
StartActual
Jan 1, 2021
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2027
Last update
Apr 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05800054
Responsible party
Sponsor
First posted
Apr 5, 2023
Start date
Jan 1, 2021
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 5, 2023

Study contacts

Xiaolin Ge, PhD
Contact
doctorsxl@163.com
13951818797

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nimotuzumab

Start the discussion